Search

Your search keyword '"DI MINNO, matteo nicola dario"' showing total 712 results
Start Over Author "DI MINNO, matteo nicola dario"
712 results on '"DI MINNO, matteo nicola dario"'

101. The Progression of Hemophilic Arthropathy: The Role of Biomarkers

Author

Pasta, Gianluigi, primary, Annunziata, Salvatore, additional, Polizzi, Alberto, additional, Caliogna, Laura, additional, Jannelli, Eugenio, additional, Minen, Alessandro, additional, Mosconi, Mario, additional, Benazzo, Francesco, additional, and Di Minno, Matteo Nicola Dario, additional

Published
2020
Full Text
View/download PDF

107. Relationship Between Plasma Osteopontin and Arginine Pathway Metabolites in Patients With Overt Coronary Artery Disease

Author

Moschetta, Donato, primary, Di Minno, Matteo Nicola Dario, additional, Porro, Benedetta, additional, Perrucci, Gianluca L., additional, Valerio, Vincenza, additional, Alfieri, Valentina, additional, Massaiu, Ilaria, additional, Orekhov, Alexander N., additional, Di Minno, Alessandro, additional, Songia, Paola, additional, Cavalca, Viviana, additional, Myasoedova, Veronika A., additional, and Poggio, Paolo, additional

Published
2020
Full Text
View/download PDF

114. Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis

Author

Bettiol, Alessandra, primary, Emmi, Giacomo, additional, Finocchi, Martina, additional, Silvestri, Elena, additional, Urban, Maria Letizia, additional, Mattioli, Irene, additional, Scalera, Antonella, additional, Lupoli, Roberta, additional, Vannacci, Alfredo, additional, Di Minno, Matteo Nicola Dario, additional, and Prisco, Domenico, additional

Published
2020
Full Text
View/download PDF

118. Contributors

Author

de Agostini, Ariane I., primary, Ai, Xingbin, additional, Bame, Karen J., additional, Casu, Benito, additional, Capila, Ishan, additional, Dager, William E., additional, Desai, Umesh R., additional, Di Minno, Matteo Nicola Dario, additional, Dong, Ji-Cui, additional, Edelman, Elazer R., additional, Edens, R. Erik, additional, Emerson, Charles P., additional, Fareed, Jawed, additional, Fuller, Maria, additional, Forsten-Williams, Kimberly, additional, Garg, Hari G., additional, Greer, Ian A., additional, Gunay, Nur Sibel, additional, Hales, Charles A., additional, Harmer, Nicholas J., additional, Hoppensteadt, Debra A., additional, Hopwood, John J., additional, Hosseini, Ghamartaj, additional, Huntington, James A., additional, Iqbal, Omer, additional, Jeske, Walter P., additional, Karnovsky, Morris J., additional, Kinsella, Michael G., additional, Kitagawa, Hiroshi, additional, Korkmaz, Mehmet E., additional, Kusche-Gullberg, Marion, additional, Lindahl, Ulf, additional, Linhardt, Robert J., additional, Liu, Caini, additional, Liu, Dongfang, additional, Meikle, Peter J., additional, Mizumoto, Shuji, additional, Mousa, Shaker A., additional, Munoz, Eva M., additional, Naggi, Annamaria, additional, Noti, Christian, additional, Nugent, Matthew A., additional, Princivalle, Marc, additional, Rudd, Tim, additional, Sasisekharan, Ram, additional, Seeberger, Peter H., additional, Shriver, Zachary, additional, Skidmore, Mark A., additional, Sugahara, Kazuyuki, additional, Thomson, Andrew A., additional, Tufano, Antonella, additional, Turnbull, Jeremy E., additional, Velleman, Sandra G., additional, Venkataraman, Ganesh, additional, Walenga, Jeanine M., additional, Warkentin, Theodore E., additional, Wight, Thomas N., additional, Yates, Edwin A., additional, and Yu, Haining, additional

Published
2005
Full Text
View/download PDF

119. Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis

Author

Peluso,Rosario, Caso,Francesco, Tasso,Marco, Sabbatino,Vincenzo, Lupoli,Roberta, Di Minno,Matteo Nicola Dario, Ursini,Francesco, Costa,Luisa, and Scarpa,Raffaele

Subjects
Research and Reviews [Open Access Rheumatology]
Abstract

Rosario Peluso,1 Francesco Caso,1 Marco Tasso,1 Vincenzo Sabbatino,1 Roberta Lupoli,2 Matteo Nicola Dario Di Minno,3 Francesco Ursini,4 Luisa Costa,1 Raffaele Scarpa1, On behalf of CaRRDs study group1Department of Clinical Medicine and Surgery, Rheumatology Research Unit, Federico II University, Naples, Italy; 2Department of Clinical Medicine and Surgery, Division of Internal Medicine, Federico II University, Naples, Italy; 3Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University, Naples, Italy; 4Internal Medicine Unit, Department of Medical Sciences, University of Ferrara, Ferrara, ItalyBackground: Psoriatic arthritis (PsA) is a chronic immune-mediated disease. It is associated with an increase in cardiovascular risk factors (obesity, hypertension, diabetes, and dyslipidemia), giving a higher risk of major adverse cardiovascular events. Patients with PsA have an increased incidence of subclinical atherosclerosis and endothelial dysfunction. The aim of this study is to perform a review of the biomarkers of subclinical atherosclerosis in patients with PsA.Methods: A search was performed in the electronic databases (PubMed, Web of Science, Scopus, and Embase) up until July 2017. Studies were considered if they included data on biomarkers of subclinical atherosclerosis in PsA, and each article was then reviewed for quality and clinical relevance. After completing the literature search, all screened literature was summarized and discussed in our study group (CaRRDs study group).Results: The initial search produced 532 abstracts, which were limited to 258 potentially relevant articles by preliminary review of the titles and by excluding review articles and case reports (n=274). A further 102 articles were deemed ineligible after examining the abstracts. Full texts of the remaining 156 articles were retrieved. Most articles were excluded because they were not relevant to the biomarkers of subclinical atherosclerosis in psoriasis and/or PsA. In the end, 54 articles were deemed eligible for this review.Conclusion: Patients with PsA showed more severe atherosclerotic disease compared with patients with only psoriasis. This may have been due to the higher systemic inflammatory burden from the combination of both diseases. In patients with PsA some molecules may be considered as markers of atherosclerotic disease, and their detection may be a prognostic marker, in addition to imaging procedures, for the development of atherosclerotic disease, and could be suitable for the management of patients with PsA.Keywords: psoriatic disease, insulin resistance, lipid profile, serum uric acid, complement C3, primary and secondary hemostasis

Published
2019

120. Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres.

Author

Di Minno, Matteo Nicola Dario, Napolitano, Mariasanta, Giuffrida, Anna Chiara, Baldacci, Erminia, Carulli, Christian, Boccalandro, Elena, Bruno, Clarissa, Forneris, Eleonora, Ricca, Irene, Passeri, Walter, Martinelli, Marco, Rivolta, Gianna Franca, Solimeno, Luigi Piero, Martinoli, Carlo, Rocino, Angiola, Pasta, Gianluigi, Aru, Brigida, Balestri, Elena, Biasoli, Chiara, and Cantori, Isabella

Subjects
HEALTH facilities, SYNOVITIS, HEMOPHILIA, JOINT diseases, DIAGNOSIS, JOINT pain
Abstract

Summary: Although synovitis is recognized as a marker of joint disease activity, its periodic assessment is not included in routine clinical surveillance of patients with haemophilia (PwH). In order to evaluate the current knowledge and to identify controversial issues, a preliminary literature search by the Musculoskeletal Committee of the Italian Association of Haemophilia Centres (AICE) has been conducted. Statements have been established and sent to the Italian AICE members to collect their level of agreement or disagreement by a Delphi process. Thirty‐seven consensus recommendations have been drafted. We found a general agreement on the indication to consider the presence of synovitis as a marker of joint disease activity in PwH. Accordingly, there was agreement on the indication to search for synovitis both in patients reporting joint pain and in asymptomatic ones, recognizing ultrasound as the most practical imaging technique to perform periodic joint screening. Interestingly, after detection of synovitis, there was agreement on the indication to modify the therapeutic approach, suggesting prophylaxis in patients treated on demand and tailoring treatment in patients already under prophylaxis. Whereas the need of an early consultation with a physiotherapist is recommended for PwH affected by chronic synovitis, the exact timing for an orthopaedic surgeon consultation is currently unknown. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

122. A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia

Author

Di Taranto, Maria Donata, primary, Giacobbe, Carola, additional, Buonaiuto, Alessio, additional, Calcaterra, Ilenia, additional, Palma, Daniela, additional, Maione, Giovanna, additional, Iannuzzo, Gabriella, additional, Di Minno, Matteo Nicola Dario, additional, Rubba, Paolo, additional, and Fortunato, Giuliana, additional

Published
2020
Full Text
View/download PDF

125. Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study

Author

Napolitano, Mariasanta, primary, Raso, Simona, additional, Mansueto, Maria Francesca, additional, Mancuso, Salvatrice, additional, Di Minno, Matteo Nicola Dario, additional, Scaturro, Dalila, additional, Mauro, Giulia Letizia, additional, Di Minno, Giovanni, additional, and Siragusa, Sergio, additional

Published
2019
Full Text
View/download PDF

129. Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor-α Blockers

Author

DI MINNO, matteo nicola dario, PELUSO, ROSARIO, LUPOLI, ROBERTA, SCARPA, RAFFAELE, DI MINNO, GIOVANNI, TARANTINO, GIOVANNI, Iervolino S, Russolillo A, CaRRDS Study Group, DI MINNO, matteo nicola dario, Iervolino, S, Peluso, Rosario, Russolillo, A, Lupoli, Roberta, Scarpa, Raffaele, DI MINNO, Giovanni, Tarantino, Giovanni, and CaRRDS Study, Group

Subjects
Adult, Male, medicine.medical_specialty, Immunology, Arthritis, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Gastroenterology, Receptors, Tumor Necrosis Factor, Etanercept, Psoriatic arthritis, Rheumatology, Internal medicine, medicine, Adalimumab, Humans, Immunology and Allergy, Prospective Studies, Prospective cohort study, Ultrasonography, Tumor Necrosis Factor-alpha, business.industry, Arthritis, Psoriatic, Antibodies, Monoclonal, Middle Aged, medicine.disease, Infliximab, Fatty Liver, Endocrinology, Antirheumatic Agents, Immunoglobulin G, Female, Liver function, Steatosis, business, Follow-Up Studies, medicine.drug
Abstract

Objective.Little is known about tumor necrosis factor-α (TNF-α) blockers, disease activity, and liver steatosis (hepatic steatosis; HS) in subjects with psoriatic arthritis (PsA). We prospectively evaluated changes in HS during treatment with TNF-α blockers.Methods.In 48 patients with PsA who had evidence of HS before the beginning of TNF-α blocker treatment, an ultrasound followup examination was performed after a 12-month treatment period with TNF-α blockers. All subjects were stratified according to minimal disease activity (MDA) or not (n-MDA), during treatment with TNF-α blockers. Changes in grade of HS were evaluated in parallel in 42 controls with HS and without PsA.Results.At baseline, no significant difference in HS score was found between PsA subjects and controls (HS scores 1.46 ± 0.65 vs 1.62 ± 0.66, respectively; p = 0.249). At 12-month followup, a worsening HS score was found in 20 (41.7%) patients with PsA and in 6 (14.3%) controls (p = 0.005). Overall, the grade of HS worsening was higher in patients with PsA (0.37 ± 0.70) than in controls (0.09 ± 0.43; p = 0.028). A significantly lower prevalence of worsening HS was found among patients with PsA with MDA, compared with n-MDA subjects (16.7% vs 66.7%, respectively; p = 0.001). Laboratory measures of liver function behaved similarly. The risk of worsening HS in patients with PsA who had MDA was similar to that in controls (HR 1.20, 95% CI 0.34–4.33, p = 0.77), and higher in patients who did not have MDA (HR 4.46, 95% CI 1.73–11.47, p = 0.001, regression analysis).Conclusion.Compared with patients with MDA, those with active disease after 12-month treatment with TNF-α blockers exhibited significantly higher incidence of worsening liver steatosis.

Published
2012
Full Text
View/download PDF

131. Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Final Results from Extension Studies.

Author

Di Minno, Matteo Nicola Dario, Minno, Alessandro Di, Calcaterra, Ilenia, Cimino, Ernesto, Dell'Aquila, Francesco, and Franchini, Massimo

Subjects
*BLOOD coagulation factor VIII, *HEMOPHILIA, *VON Willebrand disease, *HEMOPHILIA treatment, *CHILD patients
Abstract

The dose may be adjusted based on patient response in the range of 25-65 IU/kgIn some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary40-50 IU/kg twice weekly in 3- to 4-d intervals. 4 Including 57 patients receiving prophylaxis every 5 days with an ABR of 2.10 (1.54-2.86) and 15 patients receiving prophylaxis every 7 days with an ABR of 2.74 (1.44-5.20). Indeed, A-LONG and PROTECT were based on tailored prophylaxis schedules, whereas PROLONGATE and PATHFINDER 2 were characterized by a fixed-dose prophylaxis approach. [Extracted from the article]

Published
2022
Full Text
View/download PDF

132. Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies.

Author

Di Minno, Matteo Nicola Dario, Di Minno, Alessandro, Calcaterra, Ilenia, Cimino, Ernesto, Dell'Aquila, Francesco, and Franchini, Massimo

Subjects
*HEMOPHILIA, *STERIC hindrance, *POLYETHYLENE glycol, *PHYSICAL activity
Abstract

The development of enhanced half-life recombinant factor VIII (EHL-rFVIII) concentrates has improved the management of hemophilia. Furthermore, the chance of maintaining higher trough levels has allowed higher protection from bleeding and, in turn, improved safely performance for certain types of physical activity. The first technology used to improve the pharmacokinetic profile of factor VIII (FVIII) was fusion with the Fc domain of immunoglobulin G. More recently, conjugation to hydrophilic polymers of polyethylene glycol (PEG) has been demonstrated to prolong plasma half-life of FVIII by means of a reduction in clearance of the molecule due to steric hindrance by PEG covering the protein. Here we report results of a systematic review of pivotal studies on EHL-rFVIII concentrates. Significant heterogeneity is observed among different studies on EHL-rFVIII concentrates, and direct comparisons should be avoided. The annualized bleeding rate has ranged between 1.2 and 1.9 in different EHL-rFVIII concentrates, with a progressive further decrease during extension phases of pivotal studies. Zero bleeding was reported by 40 to 45% of patients. Overall, the emerging treatment options seem to be highly effective and safe, associated with a decreased dosing interval to twice weekly or less, which reduces, but does not entirely eliminate, the burden of treatment. Overall, further information is needed from real-life settings to permit differentiation between EHL-FVIII concentrates and for individualizing treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

134. Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies

Author

Di Minno, Matteo Nicola Dario, primary, Emmi, Giacomo, additional, Ambrosino, Pasquale, additional, Scalera, Antonella, additional, Tufano, Antonella, additional, Cafaro, Giovanni, additional, Peluso, Rosario, additional, Bettiol, Alessandra, additional, Di Scala, Gerardo, additional, Silvestri, Elena, additional, and Prisco, Domenico, additional

Published
2018
Full Text
View/download PDF

136. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management

Author

Franchini, Massimo, Castaman, Giancarlo, Coppola, Antonio, Santoro, Cristina, Zanon, Ezio, Di Minno, Giovanni, Morfini, Massimo, Santagostino, Elena, Rocino, Angiola, Abbate, Rosanna, Aru, Anna Brigida, Biasoli, Chiara, Borchiellini, Alessandra, Caimi, Teresa Maria, Cantori, Isabella, Cerbone, Anna Maria, Cesaro, Simone, Ciabatta, Carlo, Coluccia, Antonella, Contino, Laura, Cultrera, Dorina, De Cristofaro, Raimondo, Delios, Grazia, Di Minno, Matteo Nicola Dario, Dragani, Alfredo, Ettorre, Cosimo Pietro, Feola, Giulio, Gamba, Gabriella, Gandini, Giorgio, Giuffrida, Anna Chiara, Giuffrida, Gaetano, Gresele, Paolo, Hassan, Hamisa Jane, Lassandro, Giuseppe, Latella, Caterina, Linari, Silvia, Luciani, Matteo, Mancuso, Maria Elisa, Marchesini, Emanuela, Marino, Renato, Matino, Davide, Mazzucconi, Maria Gabriella, Messina, Maria, Milan, Marta, Molinari, Angelo Claudio, Napolitano, Mariasanta, Notarangelo, Lucia Dora, Peyvandi, Flora, Pollio, Berardino, Radossi, Paolo, Riccardi, Federica, Riva, Silvia, Rivolta, Gianna Franca, Rossetti, Gina, Santoro, Rita Carlotta, Serino, Maria Luisa, Schiavulli, Michele, Schiavoni, Mario, Schinco, Piercarla, Solimeno, Luigi Piero, Sottilotta, Gianluca, Targhetta, Roberto, Tagliaferri, Annarita, Testa, Sophie, Todisco, Angela, Turello, Marina, Valdrè, Lelia, Franchini M., Castaman G., Coppola A., Santoro C., Zanon E., Di Minno G., Morfini M., Santagostino E., Rocino A., Abbate R., Aru A.B., Biasoli C., Borchiellini A., Caimi T.M., Cantori I., Cerbone A.M., Cesaro S., Ciabatta C., Coluccia A., Contino L., Cultrera D., De Cristofaro R., Delios G., Di Minno M.N.D., Dragani A., Ettorre C.P., Feola G., Gamba G., Gandini G., Giuffrida A.C., Giuffrida G., Gresele P., Hassan H.J., Lassandro G., Latella C., Linari S., Luciani M., Mancuso M.E., Marchesini E., Marino R., Matino D., Mazzucconi M.G., Messina M., Milan M., Molinari A.C., Napolitano M., Notarangelo L.D., Peyvandi F., Pollio B., Radossi P., Riccardi F., Riva S., Rivolta G.F., Rossetti G., Santoro R.C., Serino M.L., Schiavulli M., Schiavoni M., Schinco P., Solimeno L.P., Sottilotta G., Targhetta R., Tagliaferri A., Testa S., Todisco A., Turello M., Valdre L., Franchini, Massimo, Castaman, Giancarlo, Coppola, Antonio, Santoro, Cristina, Zanon, Ezio, DI MINNO, Giovanni, Morfini, Massimo, Santagostino, Elena, Rocino, Angiola, Group Author: Abbate, Rosanna, Aru, Anna Brigida, Biasoli, Chiara, Borchiellini, Alessandra, Caimi, Teresa Maria, Cantori, Isabella, Cerbone, Anna Maria, Cesaro, Simone, Ciabatta, Carlo, Coluccia, Antonella, Contino, Laura, Cultrera, Dorina, De Cristofaro, Raimondo, Delios, Grazia, DI MINNO, matteo nicola dario, Dragani, Alfredo, Ettorre, Cosimo Pietro, Feola, Giulio, Gamba, Gabriella, Gandini, Giorgio, Giuffrida, Anna Chiara, Giuffrida, Gaetano, Gresele, Paolo, Hassan, Hamisa Jane, Lassandro, Giuseppe, Latella, Caterina, Linari, Silvia, Luciani, Matteo, Mancuso, Maria Elisa, Marchesini, Emanuela, Marino, Renato, Matino, Davide, Mazzucconi, Maria Gabriella, Messina, Maria, Milan, Marta, Molinari, Angelo Claudio, Napolitano, Mariasanta, Notarangelo, Lucia Dora, Peyvandi, Flora, Pollio, Berardino, Radossi, Paolo, Riccardi, Federica, Riva, Silvia, Rivolta, Gianna Franca, Rossetti, Gina, Santoro, Rita Carlotta, Serino, Maria Luisa, Schiavulli, Michele, Schiavoni, Mario, Schinco, Piercarla, Solimeno, Luigi Piero, Sottilotta, Gianluca, Targhetta, Roberto, Tagliaferri, Annarita, Testa, Sophie, Todisco, Angela, Turello, Marina, and Valdrè, Lelia

Subjects
Male, Autoantibodies, Blood Coagulation Factor Inhibitors, Female, Humans, Hemophilia A, Immunology and Allergy, Hematology, Blood Coagulation Factor Inhibitor, Recommendation, Autoantibodie, Human
Published
2015

141. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

Author

D’Arena, Giovanni, primary, Simeon, Vittorio, additional, Laurenti, Luca, additional, Cimminiello, Michele, additional, Innocenti, Idanna, additional, Gilio, Michele, additional, Padula, Angela, additional, Vigliotti, Maria Luigia, additional, De Lorenzo, Sonya, additional, Loseto, Giacomo, additional, Passarelli, Anna, additional, Di Minno, Matteo Nicola Dario, additional, Tucci, Marco, additional, De Feo, Vincenzo, additional, D’Auria, Fiorella, additional, Silvestris, Francesco, additional, Di Minno, Giovanni, additional, and Musto, Pellegrino, additional

Published
2017
Full Text
View/download PDF

142. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

Author

D’Arena, Giovanni, Simeon, Vittorio, Laurenti, Luca, Cimminiello, Michele, Innocenti, Idanna, Gilio, Michele, Padula, Angela, Vigliotti, Maria Luigia, De Lorenzo, Sonya, Loseto, Giacomo, Passarelli, Anna, Di Minno, Matteo Nicola Dario, Tucci, Marco, De Feo, Vincenzo, D'Auria, Fiorella, Silvestris, Francesco, Di Minno, Giovanni, Musto, Pellegrino, Laurenti, Luca (ORCID:0000-0002-8327-1396), D’Auria, Fiorella, D’Arena, Giovanni, Simeon, Vittorio, Laurenti, Luca, Cimminiello, Michele, Innocenti, Idanna, Gilio, Michele, Padula, Angela, Vigliotti, Maria Luigia, De Lorenzo, Sonya, Loseto, Giacomo, Passarelli, Anna, Di Minno, Matteo Nicola Dario, Tucci, Marco, De Feo, Vincenzo, D'Auria, Fiorella, Silvestris, Francesco, Di Minno, Giovanni, Musto, Pellegrino, Laurenti, Luca (ORCID:0000-0002-8327-1396), and D’Auria, Fiorella

Abstract

Rituximab is an effective treatment for CD20 + B-cell malignancies and autoimmune disorders. However, adverse drug reactions (ADRs) may occur after rituximab infusion, causing, in rare cases, its discontinuation. In this multicenter, retrospective study, among 374 patients treated with rituximab i.v., 23.5% experienced ADRs. Mean follow-up was 20.6 months (range 8–135). Overall, ADRs were significantly more frequent in non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemias (25–35.9%), than in autoimmune diseases (9.4–17.5%) (p <.0001). Grade 3–4 toxicity was observed in eight patients (2.1%), and in four of them (1% of all patients) definitive drug discontinuation was necessary. Interestingly, three groups of patients with different risk of developing ADR were identified, according to a predictive heat-map developed combining four parameters (splenomegaly, history of allergy, hemoglobin levels and gender) selected by multivariate analysis. This model may be useful in identifying patients at higher risk of ADRs, needing appropriate preventing therapies.

Published
2017

143. Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis on TNF-α Blockers

Author

DI MINNO, matteo nicola dario, PELUSO, ROSARIO, LUPOLI, ROBERTA, SCARPA, RAFFAELE, DI MINNO, GIOVANNI, Iervolino, S, Russolillo, A, Tarantino, G., DI MINNO, matteo nicola dario, Iervolino, S, Peluso, Rosario, Russolillo, A, Lupoli, Roberta, Scarpa, Raffaele, DI MINNO, Giovanni, and Tarantino, G.

Subjects
Hepatic Steatosi, Disease Activity, Psoriatic Arthriti, TNF-α Blockers
Abstract

OBJECTIVE: Little is known about tumor necrosis factor-α (TNF-α) blockers, disease activity, and liver steatosis (hepatic steatosis; HS) in subjects with psoriatic arthritis (PsA). We prospectively evaluated changes in HS during treatment with TNF-α blockers. METHODS: In 48 patients with PsA who had evidence of HS before the beginning of TNF-α blocker treatment, an ultrasound followup examination was performed after a 12-month treatment period with TNF-α blockers. All subjects were stratified according to minimal disease activity (MDA) or not (n-MDA), during treatment with TNF-α blockers. Changes in grade of HS were evaluated in parallel in 42 controls with HS and without PsA. RESULTS: At baseline, no significant difference in HS score was found between PsA subjects and controls (HS scores 1.46 ± 0.65 vs 1.62 ± 0.66, respectively; p = 0.249). At 12-month followup, a worsening HS score was found in 20 (41.7%) patients with PsA and in 6 (14.3%) controls (p = 0.005). Overall, the grade of HS worsening was higher in patients with PsA (0.37 ± 0.70) than in controls (0.09 ± 0.43; p = 0.028). A significantly lower prevalence of worsening HS was found among patients with PsA with MDA, compared with n-MDA subjects (16.7% vs 66.7%, respectively; p = 0.001). Laboratory measures of liver function behaved similarly. The risk of worsening HS in patients with PsA who had MDA was similar to that in controls (HR 1.20, 95% CI 0.34-4.33, p = 0.77), and higher in patients who did not have MDA (HR 4.46, 95% CI 1.73-11.47, p = 0.001, regression analysis). CONCLUSION: Compared with patients with MDA, those with active disease after 12-month treatment with TNF-α blockers exhibited significantly higher incidence of worsening liver steatosis.

Published
2012

144. Management of patients with factor V deficiency: open issues from the challenging history of a woman with anaphylactic transfusion reactions

Author

Coppola A., Maruotti G. M., Feola G., Catalano A., Quaglia F., Tomaiuolo M., Cerbone A. M., Margaglione M., DI MINNO, matteo nicola dario, MARTINELLI, PASQUALE, Coppola, A., Maruotti, G. M., Feola, G., Catalano, A., Quaglia, F., Tomaiuolo, M., DI MINNO, matteo nicola dario, Cerbone, A. M., Margaglione, M., and Martinelli, Pasquale

Subjects
Management factor V deficiency transfusion
Published
2010

147. Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study

Author

Tarantino, Luciano, primary, Busto, Giuseppina, additional, Nasto, Aurelio, additional, Fristachi, Raffaele, additional, Cacace, Luigi, additional, Talamo, Maria, additional, Accardo, Catello, additional, Bortone, Sara, additional, Gallo, Paolo, additional, Tarantino, Paolo, additional, Nasto, Riccardo Aurelio, additional, Di Minno, Matteo Nicola Dario, additional, and Ambrosino, Pasquale, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results